Zydus Cadila Receives Final USFDA Nod for Glaucoma Drug – CORPORATE ETHOS

Zydus Cadila Receives Final USFDA Nod for Glaucoma Drug

By: | January 17, 2019
Zydus-Cadila

Zydus Cadila has received the final approval from the USFDA to market Acetazolamide ER Capsules (US RLD —Diamox). It will be manufactured at the group’s formulations
manufacturing facility at Moraiya, Ahmedabad.

Acetazolamide is a potent carbonic anhydrase inhibitor. Acetazolamide ER capsules are used to treat certain types of glaucoma (caused by increased ocular pressure) and to treat or prevent altitude sickness (acute mountain sickness).

The group now has 246 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.